

## ERYTECH to host a webcast on September 29, 2015 for its 2015 half-year results

**Lyon (France), September 22, 2015** – ERYTECH Pharma (Euronext Paris: ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, will announce its half-year results for 2015 on Monday September 28, 2015, after market close, and hold a presentation webcast on the September 29, 2015 at 2:30 pm CET / 8:30 am EDT.

Erytech’s CEO, Gil Beyen, Yann Godfrin, CSO, Iman El-Hariry, CMO, and Eric Soyer, CFO-COO, will host a conference call and webcast during which the half-year results for 2015 and recent ERYTECH developments will be presented, followed by a Q&A session.

Please dial the following numbers to participate:

<b>USA:</b>	+1 8778874163	<b>United-Kingdom:</b>	+44 2030432440
<b>Switzerland:</b>	+41 225809022	<b>Germany:</b>	+49 69222229031
<b>France:</b>	+33 172001510	<b>Belgium:</b>	+32 24029640
<b>Sweden:</b>	+46 850334664	<b>Finland:</b>	+358 942599700
<b>Netherlands:</b>	+ 31 107138194		

Confirmation Code: **215991#**

The webcast can be followed live online via the link:

<https://www.anywhereconference.com/?UserAudioMode=DATA&Name=&Conference=135296299&PIN=215991>

**About ERYTECH and ERY-ASP (GRASPA®):** [www.erytech.com](http://www.erytech.com)

Created in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. The company has recently announced positive efficacy and safety results from its completed Phase 2/3 pivotal clinical trial in Europe with its lead candidate product, ERY-ASP, also known under the trade name GRASPA®, in children and adults with relapsed or refractory ALL. ERYTECH also has an ongoing Phase 1 clinical trial of

ERY-ASP in the United States in adults with newly diagnosed ALL, and a Phase 2 clinical trial in Europe evaluating GRASPA as a first-line therapy for the treatment of elderly patients with AML, each in combination with chemotherapy.

ERY-ASP consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells, from circulating blood plasma.

Every year over 50,000 patients in Europe and the United States are diagnosed with ALL or AML. For about 80% of these patients, mainly adults and relapsing patients, current forms of L-asparaginase cannot be used due to their toxicity or as a result of allergic reactions. ERYTECH believes that the safety and efficacy profile of ERY-ASP/GRASPA, as observed in its Phase 2/3 pivotal clinical trial, offers an attractive alternative option for the treatment of leukemia patients.

ERYTECH believes that ERY-ASP has the potential as a treatment approach in solid tumors and is conducting a Phase 2 clinical trial in Europe in patients with metastatic pancreatic cancer. In addition to its current product candidates that focus on using encapsulated enzymes to induce tumor starvation, ERYTECH is exploring the use of its platform for developing cancer vaccines and enzyme replacement therapies.

The EMA and the US Food and Drug Administration (FDA) have granted orphan drug designations to ERY-ASP/GRASPA for the treatment of ALL, AML and pancreatic cancer. ERYTECH produces ERY-ASP at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). The Company has entered into licensing and distribution partnership agreements for ERY-ASP for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, who will market the product under the GRASPA® brand name.

*ERYTECH is listed on Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. ERYTECH is also listed in the US under an ADR level 1 program (OTC, ticker EYRY).*

## CONTACTS

### ERYTECH

**Gil Beyen**

*Chairman and CEO*

Tel: +33 4 78 74 44 38

[investors@erytech.com](mailto:investors@erytech.com)

### NewCap

**Julien Perez / Emmanuel Huynh**

Investor relations

**Nicolas Merigeau**

Press relations

Tel: +33 1 44 71 98 52

[erytech@newcap.fr](mailto:erytech@newcap.fr)



## Forward-looking information

This document may contain forward-looking statements and estimates with respect to the financial position, results of operations, business strategy, plans, objectives and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers ([www.amf-france.org](http://www.amf-france.org)), also available on our website ([www.erytech.com](http://www.erytech.com)) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any change in events,

conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.